An Open Label Study to Evaluate the Pharmacokinetics of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 mcg) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects
Latest Information Update: 29 Aug 2023
Price :
$35 *
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 30 Nov 2016 Status changed from active, no longer recruiting to completed.
- 14 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 19 Sep 2016 Status changed from not yet recruiting to recruiting.